Guru Gyan
Published in

Guru Gyan

A Mysterious Thing Called As Gene Editing

Sounds like science fiction, but it’s actually not!

Before we head into today’s article, we wanted to say that we have tried something different today because all of the internet is filled with articles related to the coronavirus. So, we wanted to give you a breather but also, wanted to keep you updated on futuristic technologies and we hope you enjoy it!

What Is Gene Editing?

Think about Spiderman and how he got his powers — a radioactive spider bites him, resulting in genetic mutation which in turn gives him superhuman abilities. So, gene editing is the process by which genetic material can be added, removed or altered anywhere in the DNA.

Much of the excitement around gene editing is driven by its potential to prevent and treat human diseases. It is being explored in research on a wide variety of diseases, which includes single-gene disorders like cystic fibrosis, hemophilia and sickle cell disease. It also holds promise for the treatment and prevention of more complex diseases, like cancer, heart disease, mental illness and HIV infection.

The Market For Gene Editing

As per a report by The Business Research Company, the global gene editing was valued at around $3.49 billion in 2018 and is anticipated to grow to $6.05 billion at a CAGR of 14.7% through 2022.

The Global Genome Editing Market is expected to touch $11.59 billion by 2027, as per the findings of a new report by Reports and Data.

In a recent study, titled Global CRISPR Genome Editing Market 2020 by Company, Regions, Type and Application, Forecast to 2025, India has been mentioned as one of the promising countries in this field. Apart from India, China, Japan, Korea and Southeast Asia have also been mentioned in the report as some of the promising countries/regions in this field in the Asia-Pacific region.

Which Firms Are Playing In This Field?

  • Editas Medicine, a Boston-based biotech, will ask for approval to restore the sight of a patient using *Crispr-Cas9 technology.

*CRISPR (clustered regularly interspaced short palindromic repeats) is a powerful tool for editing genes

  • Intellia Therapeutics, the competitor of Editas, is planning to seek US approval for its own trial in the second half of 2020. It will utilise Crispr to try to cure amyloidosis, a rare and potentially life-threatening liver condition.
  • Last year, Crispr Therapeutics became the first company to use gene-editing technology in humans by treating two patients with blood disorders. The success seen in these patients helped the firm raise over $270 million in a recent follow-on offering.

India & Gene Editing

In October 2019, researchers from the Delhi-based Institute of Genomics and Integrative Biology (IGIB) of the Council of Scientific and Industrial Research (CSIR), developed a new variant for CRISPR-Cas 9. The scientists said that this variant can increase precision in editing genome while avoiding unintended changes in DNA.

In conclusion, gene-editing has the potential to revolutionise the entire pharmaceutical industry in the future. Imagine a future where we can prevent babies from inheriting serious diseases and modify crops to improve their yields, so that we can feed more people. And we feel that world is not very far away!

Head to moneyguru’s Insight section to stay updated on all major financial news updates of the day

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store